GleamWall
中文EN

KOD Kodiak Sciences Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1468748 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-13.5%
TTM EPS YoY1.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,360.9%
ROA-115.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets94.0%
Debt / equity0.00x
Current ratio1.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.69x
Accruals ratio-36.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$58.30M$56.08M$48.55M$45.49M$50.48M$42.76M$43.64M$31.77M
SG&A expense$8.79M$10.76M$11.23M$11.96M$11.88M$12.75M$15.43M$14.41M
Operating income-$67.10M-$66.84M-$59.78M-$57.45M-$62.35M-$55.51M-$59.07M-$46.18M
Interest expense———————$0
Net income-$66.22M-$65.64M-$58.16M-$56.74M-$61.46M-$54.31M-$57.46M-$44.10M
EBITDA-$63.01M-$62.73M-$55.67M-$52.91M-$57.77M-$50.92M-$54.47M-$41.55M
EPS (basic)-1.05-1.05-0.94—-1.16-1.03-1.09—
EPS (diluted)-1.05-1.05-0.94—-1.16-1.03-1.09—
Weighted avg. shares (diluted)62.96M62.63M61.86M—52.86M52.78M52.75M—
Balance sheet
Cash & equivalents$88.68M$125.90M$169.53M$209.86M$72.04M$104.17M$138.85M$168.07M
Current assets$92.89M$131.36M$175.26M$214.82M$75.73M$107.92M$142.69M$171.94M
PP&E, net$75.64M$78.31M$81.51M$85.26M$88.91M$93.43M$97.90M$102.22M
Total assets$209.41M$256.81M$306.01M$351.53M$218.07M$256.73M$297.91M$335.58M
Current liabilities$54.74M$52.77M$49.57M$45.53M$42.43M$31.01M$30.88M$25.57M
Total liabilities$196.84M$195.72M$193.91M$194.15M$194.38M$186.44M$189.07M$185.29M
Shareholders' equity$12.57M$61.10M$112.10M$157.38M$23.69M$70.29M$108.84M$150.29M
Shares outstanding64.31M62.83M62.16M61.76M53.00M52.82M52.75M52.73M
Cash flow statement
Operating cash flow-$43.87M-$46.24M-$40.01M-$39.38M-$32.88M-$34.67M-$29.08M-$30.07M
Capital expenditure$1.98M$352,000$942,000$43,000$60,000$133,000$270,000$124,000
Free cash flow-$45.84M-$46.59M-$40.95M-$39.42M-$32.94M-$34.81M-$29.35M-$30.19M
Investing cash flow-$1.98M-$352,000-$942,000-$43,000-$60,000-$133,000-$270,000-$124,000
Financing cash flow$6.38M$2.96M$619,000$177.25M$813,000$120,000$124,000$404,000
Depreciation & amortization$4.09M$4.11M$4.11M$4.54M$4.59M$4.59M$4.60M$4.63M
Stock-based compensation$12.80M$11.61M$12.15M$13.29M$14.05M$15.64M$15.89M$8.62M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.